Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCell Receives US Patent For Fa2N-4, Ea1C-35
MultiCell Technologies has been granted US patent: 7566567 by the US Patent and Trademark Office, covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. Reportedly, Fa2N-4 and
MultiCell Technologies has been granted US patent: 7566567 by the US Patent and Trademark Office, covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. Reportedly, Fa2N-4 and
Nutra Pharma has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of stage 2 (moderate-to-severe) chronic pain. Cobroxin is claimed to be the first OTC pain
A study conducted by HerbalScience has reported that they have identified the key chemical components in elderberry, cinnamon, and green tea extracts that bind to the HIV viruses
TTY Biopharm has signed an agreement with to-BBB for the manufacturing of brain-targeted doxorubicin liposomes. These liposomes are essential for the clinical development of to-BBB’s lead product for
Phase Forward has acquired Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance. The company purchased the Covance business unit for $10m in cash. Reportedly, as part
FDA and US Centers for Disease Control and Prevention (CDC) has reaffirmed that Merck’s GARDASIL continues to be safe and effective, and its benefits continue to outweigh its
MicroPhage has launched its multi-site clinical trial to support a FDA premarket notification 510(k). The platform has been developed to rapidly identify bacterial infections and determine antibiotic susceptibility
NextPharma has engaged the services of Ron Collins, to represent its business development affairs in the Eastern part of the US and Canada. The move is in response
GEA Lyophil, part of GEA Pharma Systems, has won a milestone order from the Zhejiang Hisun Pharmaceutical in Taizhou Zhejiang, China, for the supply of pharmaceutical freeze dryers
The Medicines Company has withdrawn the European marketing authorization application (MAA) for the 200mg, 3-7 day daily dose therapy of oritavancin. Oritavancin is an investigational antibiotic drug candidate